Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

Université de Montréal

$27,000.00

Modulating vessel barrier function to control immune cell localization with hESC-islets-on-a-chip.

FY 2025-26

Summary
Type 1 diabetes (T1D) occurs when the immune system destroys the insulin-producing beta cells in pancreatic islets, leaving people dependent on lifelong insulin therapy. A promising alternative is replacing these cells through islet transplantation, including islets made from human embryonic stem cells. However, transplanted islets often struggle to survive due to low oxygen levels and inflammation. We previously showed that adding blood vessels can help to improve islet survival and function, but this may also create a path for immune cells to reach and damage the graft. Thus, our project aims to engineer blood vessels with a stronger barrier function, like the protective vessels in the brain, to prevent immune cell localization with islets. These specialized vessels still allow oxygen and small molecules, like glucose and insulin, to pass while limiting immune cell movement. To achieve this, we will generate endothelial cells and pericytes, the two main vascular cell types in islets, from human embryonic stem cells and increase the expression of key junctional proteins to enhance their barrier properties. Next, we will test whether these modified vessels reduce immune cell entry using an islet-on-a-chip system. Using this platform, we will combine stem cell-derived islets and vascular cells and circulate fluorescently labeled macrophages (a type of immune cell) through the vessel network to monitor whether they can cross the vessel wall and reach the islets. If successful, this strategy could protect transplanted islets by reducing inflammation while maintaining oxygen delivery, an approach that ultimately may help improve the success of cell-based therapies for people living with T1D.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572773
Name
Milland Théa
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Modulating vessel barrier function to control immune cell localization with hESC-islets-on-a-chip.
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Human Embryonic Stem Cells; Immune Modulation; Islet Transplantation; Microfluidics; Regenerative Medicine; Type 1 Diabetes; Vascular Barrier Function; Vascular Cells
Abstract
Type 1 diabetes (T1D) occurs when the immune system destroys the insulin-producing beta cells in pancreatic islets, leaving people dependent on lifelong insulin therapy. A promising alternative is replacing these cells through islet transplantation, including islets made from human embryonic stem cells. However, transplanted islets often struggle to survive due to low oxygen levels and inflammation. We previously showed that adding blood vessels can help to improve islet survival and function, but this may also create a path for immune cells to reach and damage the graft. Thus, our project aims to engineer blood vessels with a stronger barrier function, like the protective vessels in the brain, to prevent immune cell localization with islets. These specialized vessels still allow oxygen and small molecules, like glucose and insulin, to pass while limiting immune cell movement. To achieve this, we will generate endothelial cells and pericytes, the two main vascular cell types in islets, from human embryonic stem cells and increase the expression of key junctional proteins to enhance their barrier properties. Next, we will test whether these modified vessels reduce immune cell entry using an islet-on-a-chip system. Using this platform, we will combine stem cell-derived islets and vascular cells and circulate fluorescently labeled macrophages (a type of immune cell) through the vessel network to monitor whether they can cross the vessel wall and reach the islets. If successful, this strategy could protect transplanted islets by reducing inflammation while maintaining oxygen delivery, an approach that ultimately may help improve the success of cell-based therapies for people living with T1D.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Milland, Théa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~